COO Stock Analysis: The Cooper Companies | NASDAQ

Contact Lenses, Womens Health, Fertility Products, Medical Devices

Total Rating 36

Safety 86

Buy Signal -0.91

Medical Instruments & Supplies
Industry Rotation: +4.2

Market Cap: 10.8B
Avg Turnover: 267M

Risk 3d forecast

Volatility29.6%

VaR 5^th Pctl4.69%

VaR vs Median-3.42%

Reward TTM

Sharpe Ratio-0.75

Rel. Str. IBD6.9

Rel. Str. Peer Group11.4

Character TTM

Beta0.390

Beta Downside0.548

Hurst Exponent0.551

Drawdowns 3y

Max DD52.11%

CAGR/Max DD-0.24

CAGR/Mean DD-0.58

EPS (Earnings per Share)

EPS CAGR: 14.23%
EPS Trend: 99.7%

Last SUE: 1.19
Qual. Beats: 6

Revenue

Rev. CAGR: 6.26%
Rev. Trend: 99.4%

Last SUE: -2.47
Qual. Beats: -1

Warnings

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan +0.1% 5

Feb +1.3% 6

Mar -1.6% 5

Apr -1.5% 33

May -1.2% 20

Jun +3.9% 6

Jul +0.9% 19

Aug -0.8% 20

Sep -4.9% 31

Oct -2.9% 39

Nov +3.8% 15

Dec +3.2% 29

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: COO The Cooper Companies

The Cooper Companies, Inc. (COO) is a U.S.-based medical device company that operates through two distinct segments: CooperVision, which develops, manufactures, and markets a range of contact lenses (spherical, toric, and multifocal) targeting conditions such as astigmatism, presbyopia, and myopia; and CooperSurgical, which provides womens health and fertility products and services, including the Paragard hormone-free intrauterine device (IUD), fertility consumables and equipment, donor gamete services, genomic and genetic testing, and cord blood and cord tissue cryostorage. The company sells through a diversified channel mix spanning distributors, group purchasing organizations (GPOs), independent eye-care and health-care professionals, corporate retailers, hospitals, clinics, and authorized resellers.

Founded in 1958 and headquartered in San Ramon, California, Cooper Companies sits within the Health Care Supplies sub-industry and follows a diversified medical-device business model that combines a high-volume consumer-adjacent vision care franchise with a specialized surgical and reproductive health portfolio, reducing reliance on any single product line or end market.

Headlines to Watch Out For

Myopia management lens adoption accelerates CooperVision revenue growth
CooperSurgical fertility services expand on rising global IVF demand
Paragard litigation costs and FX volatility pressure operating margins

Piotroski VR-10 (Strict) 7.0

Net Income: 570.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.02 > 1.0
NWC/Revenue: 9.79% < 20% (prev 27.87%; Δ -18.08% < -1%)
CFO/TA 0.08 > 3% & CFO 1.03b > Net Income 570.3m
Net Debt (2.39b) to EBITDA (910.2m): 2.63 < 3
Current Ratio: 1.22 > 1.5 & < 3
Outstanding Shares: last quarter (193.4m) vs 12m ago -3.59% < -2%
Gross Margin: 63.64% > 18% (prev 66.96%; Δ -3.32% > 0.5%)
Asset Turnover: 33.83% > 50% (prev 32.69%; Δ 1.14% > 0%)
Interest Coverage Ratio: 5.56 > 6 (EBIT TTM 526.3m / Interest Expense TTM 94.6m)

Altman Z'' 4.60

A: 0.03 (Total Current Assets 2.28b - Total Current Liabilities 1.87b) / Total Assets 12.7b
B: 0.64 (Retained Earnings 8.13b / Total Assets 12.7b)
C: 0.04 (EBIT TTM 526.3m / Avg Total Assets 12.5b)
D: 1.92 (Book Value of Equity 8.33b / Total Liabilities 4.34b)
Altman-Z'' = 4.60 = AA

Beneish M -3.00

DSRI: 0.95 (Receivables 788.9m/792.3m, Revenue 4.24b/4.05b)
GMI: 1.05 (GM 66.96% / 63.64%)
AQI: 0.98 (AQ_t 0.65 / AQ_t-1 0.67)
SGI: 1.05 (Revenue 4.24b / 4.05b)
TATA: -0.04 (NI 570.3m - CFO 1.03b) / TA 12.7b)
Beneish M = -3.00 (Cap -4..+1) = AA

What is the price of COO shares?

As of October 11, 2026, the stock is trading at USD 54.37 with a total of 3,182,621 shares traded. Over the past week, the price has changed by -4.46%, over one month by -14.35%, over three months by -23.44% and over the past year by -22.05%.

Current recommended Stop Loss: 52.20 (which is 4% or 1.3 ATR below the current price).

Is COO a buy, sell or hold?

The Cooper Companies has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold COO.

StrongBuy: 3
Buy: 2
Hold: 11
Sell: 0
StrongSell: 0

What are the forecasts/targets for the COO price?

Analysts Target Price	66.2	21.8%

The Cooper Companies (COO) - Fundamental Data Overview as of 05 October 2026

Market Cap USD = 10.8b (10.8b USD * 1.0 USD.USD)
P/E Trailing = 19.5567
P/E Forward = 11.3379
P/S = 2.5542
P/B = 1.2626
P/EG = 0.5198
Revenue TTM = 4.24b USD
EBIT TTM = 526.3m USD
EBITDA TTM = 910.2m USD
Long Term Debt = 1.91b USD (from longTermDebt, last quarter)
Short Term Debt = 628.1m USD (from shortTermDebt, last quarter)
Debt = 2.55b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.20m
Net Debt = 2.39b USD (calculated: Debt 2.55b - CCE 154.7m)
Enterprise Value = 13.2b USD (10.8b + Debt 2.55b - CCE 154.7m)
Interest Coverage Ratio = 5.56 (Ebit TTM 526.3m / Interest Expense TTM 94.6m)
EV/FCF = 19.49x (Enterprise Value 13.2b / FCF TTM 678.0m)
FCF Yield = 5.13% (FCF TTM 678.0m / Enterprise Value 13.2b)
FCF Margin = 16.00% (FCF TTM 678.0m / Revenue TTM 4.24b)
Net Margin = 13.46% (Net Income TTM 570.3m / Revenue TTM 4.24b)
Gross Margin = 63.64% ((Revenue TTM 4.24b - Cost of Revenue TTM 1.54b) / Revenue TTM)
Gross Margin QoQ = 62.36% (prev 68.00%)
Tobins Q-Ratio = 1.04 (Enterprise Value 13.2b / Total Assets 12.7b)
Interest Expense / Debt = 3.72% (Interest Expense 94.6m / Debt 2.55b)
Taxrate = 33.82% (191.6m / 566.5m)
NOPAT = 348.3m (EBIT 526.3m * (1 - 33.82%))
Current Ratio = 1.22 (Total Current Assets 2.28b / Total Current Liabilities 1.87b)
Debt / Equity = 0.31 (Debt 2.55b / totalStockholderEquity, last quarter 8.33b)
Debt / EBITDA = 2.63 (Net Debt 2.39b / EBITDA 910.2m)
Debt / FCF = 3.53 (Net Debt 2.39b / FCF TTM 678.0m)
Total Stockholder Equity = 8.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.55% (Net Income 570.3m / Total Assets 12.7b)
RoE = 6.88% (Net Income TTM 570.3m / Total Stockholder Equity 8.29b)
RoCE = 5.16% (EBIT 526.3m / Capital Employed (Equity 8.29b + L.T.Debt 1.91b))
RoIC = 3.09% (NOPAT 348.3m / Invested Capital 11.3b)
WACC = 6.42% (E(10.8b)/V(13.4b) * Re(7.35%) + D(2.55b)/V(13.4b) * Rd(3.72%) * (1-Tc(0.34)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.94 | Cagr: -1.59%
[DCF] Terminal Value 77.97% ; FCFF base≈571.6m ; Y1≈655.2m ; Y5≈964.3m
[DCF] Fair Price = 63.73 (EV 14.5b - Net Debt 2.39b = Equity 12.1b / Shares 190.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.73 | EPS CAGR: 14.23% | SUE: 1.19 | # QB: 6
Revenue Correlation: 99.39 | Revenue CAGR: 6.26% | SUE: -2.47 | # QB: -1
EPS current Quarter (2027-01-31): EPS=1.10 | Chg30d=-5.99% | Revisions=+0% | Analysts=8
EPS current Year (2026-10-31): EPS=4.53 | Chg30d=-2.09% | Revisions=-83% | GrowthEPS=+9.9% | GrowthRev=+3.6%
EPS next Year (2027-10-31): EPS=4.69 | Chg30d=-6.04% | Revisions=-25% | GrowthEPS=+3.6% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: -76% (up=1, down=17)